Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ARWR

Arrowhead Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ARWR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-2.18

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 13:41 UTC.

What Arrowhead Pharmaceuticals, Inc. does

The company develops RNA interference-based medicines designed to silence disease-causing genes using its proprietary TRiM platform and various RNA chemistries. It has achieved its first commercial approval with REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome and has additional drug candidates in clinical trials across multiple phases. The company has built a commercial organization for rare disease marketing and plans to expand capabilities for larger disease markets.

Summarized from Arrowhead Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-2.18

Revenue, margins & earnings

FY2021: net loss $141M on revenue $138M$138MFY2021FY2022: net loss $176M on revenue $243M$243MFY2022FY2023: net loss $205M on revenue $241M$241MFY2023FY2024: net loss $599M on revenue $4M$4MFY2024FY2025: net loss $2M on revenue $829M$829MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-20
  • 2026-08-20DirectorSale-2,000$173.9K
  • 2026-08-20DirectorSale-11,600$1.01M
  • 2026-06-17DirectorAward11,882—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Arrowhead Pharmaceuticals, Inc. do?

The company develops RNA interference-based medicines designed to silence disease-causing genes using its proprietary TRiM platform and various RNA chemistries.

When did ARWR last file with the SEC?

Arrowhead Pharmaceuticals, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 13:41 UTC. This page is also available as JSON at /api/data?ticker=ARWR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ARWR and 5,000+ tickers.

Create a free account — keep ARWR
For your agent
GET /api/data?ticker=ARWR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt